$95.99 - $119.99 You save $55.99 - $69.99 You save $79.99 - $99.99 You save $4.79 - $5.99 You save $23.99 - $29.99 You save $39.99 - $49.99 You save $79.99 - $99.99 You save $63.99 - $79.99 You save Support when you need it
As innovators change their product lifecycle management approach towards increased patient centricity, transitioning from intravenous (IV) infusion to SC administration with an injection device can be a huge game-changer (patient focus, compliance, differentiation from competitors), with notable examples being Herceptin (trastuzumab, Roche/Genentech), MabThera (rituximab, Roche/Genentech), Actemra (tocilizumab, Roche/Genentech), Benlysta (belimumab, GSK), Entyvio (vedolizumab, Takeda) and others
doi: 10.1016/j.preteyeres.2007.01.004 98
Lakshmi Narayanan, and Rajiv D